CytoDyn Appoints Denis R. Burger, Ph.D. to Board of Directors

  CytoDyn Appoints Denis R. Burger, Ph.D. to Board of Directors

  Industry veteran with proven track record in HIV drug development bolsters
          board with scientific, operational and financial expertise

Business Wire

VANCOUVER, Wash. -- February 13, 2014

CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development
of new therapies for combating infection with immune deficiency viruses,
announced the appointment of Denis R. Burger, Ph.D. to its Board of Directors
effective February 7, 2014. Dr. Burger is a life sciences executive with over
25 years of extensive scientific, operational and financial experience in the
biotech industry.

As CEO or chairman of several biotechnology companies, Dr. Burger has led
numerous corporate financing transactions and public securities offerings and
has experience leading R&D, GMP manufacturing and clinical development
functional areas. Additionally, he holds a patent for a method of detecting
AIDS virus infection and oversaw the development of the first monoclonal
antibody approved by the FDA for clinical use. Dr. Burger joins CytoDyn’s
board as the Company prepares to advance the clinical development of PRO 140,
a leading monoclonal antibody for the treatment of HIV.

“We are very pleased to welcome Dr. Burger to the CytoDyn Board of Directors
during this important time. His scientific and industry expertise, business
acumen and experience in leading successful biotech companies will prove to be
invaluable to the Company,” said Anthony D. Caracciolo, CytoDyn’s Chairman of
the Board.

Dr. Burger commented, “The CytoDyn management team and board of directors have
identified a clear, strategic path for its first-in-class, viral entry
inhibitor product candidate, PRO 140. I am excited to join CytoDyn’s board of
directors and truly believe PRO 140 has the potential to change the treatment
paradigm for patients with HIV/AIDS.”

Dr. Burger is currently a director of Lorus Therapeutics, Inc., a cancer
therapeutics, TSX-listed company. Dr. Burger co-founded Trinity Biotech, a
NASDAQ-listed diagnostic company, in June 1992, served as its Chairman from
June 1992 to May 1995, and is currently lead independent director. Until March
2007, he was Chairman and Chief Executive Officer of AVI Biopharma Inc. (now
Sarepta Therapeutics), a NASDAQ-listed RNA therapeutics company. He was also a
co-founder of Epitope Inc. (now Orasure Technologies, NASDAQ-listed), serving
as its Chairman from 1981 to 1990. Dr. Burger previously held a professorship
in the Department of Microbiology and Immunology and Surgery (Surgical
Oncology) at the Oregon Health and Sciences University in Portland. Dr. Burger
received his undergraduate degree in Bacteriology and Immunology from the
University of California in Berkeley and his Master of Science and Ph.D.
degrees in Microbiology and Immunology from the University of Arizona.

About PRO 140

PRO 140 belongs to a new class of HIV/AIDS therapeutics -- viral-entry
inhibitors -- that are intended to protect healthy cells from viral infection.
PRO 140 is a humanized monoclonal antibody directed against CCR5, a molecular
portal that HIV uses to enter cells.

PRO 140 has been the subject of four Phase 1/1b and two Phase 2a clinical
trials, each of which demonstrated PRO 140’s ability to significantly reduce
HIV viral load in human test subjects, and has also been designated a “fast
track” product candidate by the FDA. The PRO 140 antibody appears to be a
powerful antiviral agent while not being a drug, leading to potentially fewer
side effects and less frequent dosing requirements as compared to daily drug
therapies currently in use.

About CytoDyn

CytoDyn is a biotechnology company focused on developing subcutaneously
delivered humanized cell-specific monoclonal antibodies (mAbs) as entry
inhibitors for the treatment and prevention of Human Immunodeficiency Virus
(HIV). The Company has one of the leading mAbs under development for HIV
infection, PRO 140, which is a Late Stage 2 humanized mAb with demonstrated
antiviral activity in man. PRO 140 blocks the HIV co-receptor CCR5 and
clinical trial results thus far indicate that it does not affect the normal
function of the cell. Results from Phase 1/1b and Phase 2a human clinical
trials have shown that PRO 140 can significantly reduce viral burden in people
infected with HIV. CytoDyn intends to continue to develop PRO 140 as a
therapeutic anti-viral agent in persons infected with HIV. For more
information on the Company please visit

Forward-Looking Statements

This press release includes forward-looking statements and forward-looking
information within the meaning of United States securities laws. These
statements and information represent CytoDyn’s intentions, plans,
expectations, and beliefs and are subject to risks, uncertainties and other
factors, many beyond CytoDyn’s control. These factors could cause actual
results to differ materially from such forward-looking statements or
information. The words “believe,” “estimate,” “expect,” “intend,” “attempt,”
“anticipate,” “foresee,” “plan,” and similar expressions and variations
thereof identify certain of such forward-looking statements or forward-looking
information, which speak only as of the date on which they are made.

CytoDyn disclaims any intention or obligation to publicly update or revise any
forward-looking statements or forward-looking information, whether as a result
of new information, future events or otherwise, except as required by
applicable law. Readers are cautioned not to place undue reliance on these
forward-looking statements or forward-looking information. While it is
impossible to identify or predict all such matters, these differences may
result from, among other things, the inherent uncertainty of the timing and
success of and expense associated with research, development, regulatory
approval, and commercialization of CytoDyn’s products and product candidates,
including the risks that clinical trials will not commence or proceed as
planned; products appearing promising in early trials will not demonstrate
efficacy or safety in larger-scale trials; future clinical trial data on
CytoDyn’s products and product candidates will be unfavorable; funding for
additional clinical trials may not be available; CytoDyn’s products may not
receive marketing approval from regulators or, if approved, may fail to gain
sufficient market acceptance to justify development and commercialization
costs; competing products currently on the market or in development may reduce
the commercial potential of CytoDyn’s products; CytoDyn, its collaborators or
others may identify side effects after the product is on the market; or
efficacy or safety concerns regarding marketed products, whether or not
scientifically justified, may lead to product recalls, withdrawals of
marketing approval, reformulation of the product, additional pre-clinical
testing or clinical trials, changes in labeling of the product, the need for
additional marketing applications, or other adverse events.

CytoDyn is also subject to additional risks and uncertainties, including risks
associated with the actions of its corporate, academic, and other
collaborators and government regulatory agencies; risks from market forces and
trends; potential product liability; intellectual property litigation;
environmental and other risks; and risks that current and pending patent
protection for its products may be invalid, unenforceable, or challenged or
fail to provide adequate market exclusivity. There are also substantial risks
arising out of CytoDyn’s need to raise additional capital to develop its
products and satisfy its financial obligations; the highly regulated nature of
its business, including government cost-containment initiatives and
restrictions on third-party payments for its products; the highly competitive
nature of its industry; and other factors set forth in CytoDyn’s Quarterly
Report on Form 10-Q for the quarter ended November 30, 2013 and other reports
filed with the U.S. Securities and Exchange Commission.


Investors and Media:
Jenene Thomas Communications, LLC
Jenene Thomas, 908-938-1475
Investor Relations and Corporate Communications Advisor
Press spacebar to pause and continue. Press esc to stop.